ArticleJournal of clinical medicine2021

Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS).

Annika Vestergaard Kvist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.